Outcomes of anterior chamber wash with adjuvant intracameral and intrastromal voriconazole in deep stromal fungal keratitis with endoexudates - A retrospective study

前房冲洗联合辅助性前房内和基质内注射伏立康唑治疗伴有内渗出的深层基质真菌性角膜炎的疗效——一项回顾性研究

阅读:1

Abstract

STUDY DESIGN: Retrospective observational study. PURPOSE: To analyze the clinical outcomes of patients with deep stromal fungal keratitis with endoexudates who received adjuvant anterior chamber (AC) wash with intracameral (IC) and intrastromal (IS) voriconazole. METHODS: Demographics, risk factors, clinical course, microbiology, and visual outcomes of patients with deep-seated fungal keratitis who underwent AC wash with IC and IS voriconazole from January 2022 to December 2022 with at least 6 months post-op follow-up visits were analyzed. RESULTS: The mean age of 40 patients was 53 ± 12 years, and the mean time to presentation was 12 ± 8 days. The mean size of the ulcer at presentation was 21 ± 11.7 square mm. Aspergillus flavus was the most isolated organism in 16 (40%) patients. Seven (17.5%) patients achieved complete resolution with scarring and 33 (82.5%) required therapeutic keratoplasty (TPK), out of which 10 (30.3%) had reinfection. CONCLUSION: AC wash with IC and IS voriconazole was ineffective as adjuvant therapy in cases of deep-seated fungal keratitis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。